

Pediatric Trials in Antibacterial Drug Development: Findings from the Clinical Trials Transformation Project



John Bradley, MD¹, Daniel Benjamin, Jr, MD², Amy Corneli, PhD³, Breck Gamel⁴, Gary Noel, MD⁵, Joshua Thaden, MD, PhD⁶ and Jamie N Roberts, MA, MPH³

¹Division of Infectious Diseases, Rady Children's Hospital, San Diego, CA, United States; ²Department of Pediatrics, Duke University Medical School - Duke Clinical Research Institute, Durham, NC, 27715, United States; ³Clinical Trials Transformation Initiative, Duke University, Durham, NC, 27701, United States;

⁴Patient Representative, Clinical Trials Transformation Initiative Project Team, Hewitt, TX, United States; ⁵Child Health Innovation Leadership Department, Janssen Pharmaceuticals, Raritan, NJ, United States and ⁶Department of Medicine - Infectious Diseases, Duke University School of Medicine, Durham, NC, 27715, United States.

Background


Chronic pulmonary infections are linked to poor health and high mortality in patients with cystic fibrosis. Treatment of chronic pulmonary infections is negatively impacted by the rise of antibiotic resistant infections and limited antibiotic treatment options. Under the Pediatric Research Equity Act (PREA), companies developing antibacterial drugs (AB) for adults are required to conduct pediatric trials unless a waiver is obtained. Conducting pediatric AB drug trials is more challenging than with adults, making it difficult for some companies to comply with PREA, despite considerable efforts. Our research has demonstrated that far fewer pediatric AB drug trials are conducted relative to studies on other pediatric conditions: only 110 of all interventional and observational pediatric studies registered in ClinicalTrials.gov between 2007 and 2015 (n=12,703) examined AB drugs (110/12,703, 0.9%; Table 1/Figure 1). Few studies have been conducted on the challenges of conducting pediatric clinical trials, particularly AB trials in children.

The Clinical Trials Transformation Initiative (CTTI), a public-private partnership between the Food and Drug Administration (FDA) and Duke University, implemented a project to identify the scientific and operational facilitators and challenges in conducting pediatric AB drug trials and to develop recommendations to address the challenges. This project included surveys with investigators of pediatric AB clinical trials and community providers; qualitative interviews with parents and industry representatives; and the review of the clinicaltrials.gov database described above.

Table 1: Number of antibacterial trials by infection type

Infection type	Number of Trials N=110 n (%)
Otitis media	25 (23%)
UTI	6 (5%)
Pneumonia	16 (15%)
Intra-abdominal	9 (8%)
CNS	2 (2%)
Skin	10 (9%)
Bacteremia/CLABSI	1 (1%)
Sepsis	6 (5%)
Other/Not specified	40 (36%)

Figure 1. Flow Diagram (for focused subset) Population: Study registration data downloaded from ClinicalTrials.gov on 27 September 2015



Surveys with Investigators of Pediatric Antibacterial (AB) Drug Trials and Pediatric Providers

Purpose

- Identify the severity of barriers to conducting AB drug trials among pediatric populations.

Methods

- We administered an online survey to a convenience sample of investigators and pediatric providers over a 5-week period in August and September 2015.
- We presented investigators with 36 potential barriers to pediatric AB drug trials, arranged in six categories:
 - (1) ethics and regulatory, (2) study protocol, (3) parental concerns, (4) parent and child logistics, (5) colleagues' concerns, and (6) miscellaneous
- We presented pediatric providers with 30 potential barriers to serving as a site for pediatric clinical trials, arranged in four categories: (1) study implementation, (2) ethics and regulatory, (3) parental concerns, and (4) parental and child logistics.

Results

PEDIATRIC PROVIDERS

Demographics

Of the 136 providers surveyed, 52/136 (38%) had previously referred a pediatric patient to a clinical trial, and only 17/136 (12%) had ever been an investigator for a pediatric trial (Table 2).

Barriers

- All potential barriers were classified as ["somewhat," "moderate," or "major"] by the majority of providers (Tables 3 and 4).
- Providers perceived greater challenges related to parental concerns and parent or child logistical barriers than study implementation and ethics or regulatory barriers.

INVESTIGATORS

Demographics

- Of the 74 investigators surveyed, most were specialists in pediatric infectious diseases (47%, n=35) or were neonatologists (23%, n=17).
- The majority of participants had conducted pediatric AB trials for more than 10 years (53%, n=39) and at academic children's hospitals (87%, n=64) (Table 5).
- Among those who conducted research in a hospital setting (n=71), almost all hospitals had a neonatal intensive care unit (97%, n=69).

Barriers

- Each factor was found to be a barrier ("somewhat," "moderate," or "major") by a considerable percentage of participants (range: 47.9% to 98.6%) (Tables 6 and 7).
- In comparison with the other categories, almost all of the factors presented in the parental concern category were identified as a barrier ("somewhat," "moderate," or "major") by a high percentage of participants (>80%).

Conclusions

- Pediatric providers and investigators perceive many barriers to participating in or conducting pediatric AB drug trials.
- Findings suggest that further engagement with parents is needed (see section on parent interviews).
- The identification of these barriers is key to designing effective interventions.

Table 2: Pediatric Provider Characteristics, n (%)

	N=136
Specialty	
Pediatric Infectious Disease	15 (11)
General Pediatrics	45 (33)
Pediatric Hospitalist	21 (15)
Family Medicine	55 (40)
Years practicing medicine	
< 5 years	9 (7)
5-10 years	14 (11)
> 10 years	110 (83)
Approximate distance from practice/institution to the nearest academic medical center or children's hospital	
Practice is located in an academic medical center or children's Hospital	23 (17)
< 30 minutes	70 (52)
30 minutes to 2 hours	39 (29)
> 2 hours	4 (3)

Table 3: Pediatric provider perceptions of potential study implementation and ethics regulatory barriers to pediatric clinical trial implementation, %.

Study Implementation	Not a barrier	Somewhat	Moderate	Major	N/A	Not sure
Obtaining funding for research costs	4.3	18.1	28.8	41.7	1.6	5.5
Initially training site staff in research	11.7	28.8	27.3	22.0	0.8	2.3
Reaching the required number of study patients	11.0	29.1	36.7	23.6	1.6	3.9
Having site staff for patient enrollment	19.3	22.8	26.6	31.5	0.8	1.6
Recruiting study patients from your practice	18.0	34.4	36.4	18.9	0.8	1.6
Impact on non-research clinical work flow	15.6	28.6	31.3	21.1	1.6	3.9
Length of patient study visits	23.0	27.8	34.9	9.6	2.4	2.4
Finding office space for administration	32.0	25.8	19.5	20.3	1.6	0.8
Frequency of patient study visits	31.5	28.0	28.0	12.4	2.4	1.6
Finding clinic space for patient study visits	35.2	25.0	20.3	15.4	2.4	1.6
Ethical and Regulatory						
Preparing required regulatory documents	8.9	17.1	30.9	38.2	0.8	3.3
Addressing IRB questions and concerns	12.9	32.3	29.8	21.0	0.8	3.2
Obtaining parental consent	24.4	34.1	23.6	15.4	0.8	1.6
Obtaining child assent	23.6	42.3	20.3	8.9	2.4	2.4

Table 4: Pediatric provider perceptions of potential parental concerns and parent or child logistical barriers to pediatric clinical trial implementation, %.

Parental Concerns	Not a barrier	Somewhat	Moderate	Major	N/A	Not sure
Concerns about side effects of the drug	3.9	15.0	34.2	41.7	0	3.1
Concerns about the number of invasive procedures	3.9	17.3	34.9	39.4	0	3.1
Concerns about child taking a drug not previously tested in children	7.1	18.1	32.3	39.4	0	2.4
Concerns about the number of blood draws	5.5	21.3	43.3	29.2	0	4.7
Perception that the child will be at increased risk for physical harm	8.7	18.3	38.9	31.0	0	3.2
Perception of insufficient study benefits for child	8.7	31.5	31.5	25.2	0	3.1
Concerns about consent length and complexity	9.5	31.7	38.1	19.5	0	3.2
Concerns about being randomized to placebo	11.0	32.3	30.7	24.4	0	1.6
Concerns about blinding/not knowing what drug their child is taking	11.8	22.6	38.6	23.6	0	2.4
Parent and Child Logistics						
Parents' work schedules	2.4	21.8	39.5	33.1	0	3.2
Children's school schedules	6.4	28.4	39.3	28.4	0	1.6
Transportation difficulties for parents/children	7.9	38.2	27.3	23.0	0	1.6
Insufficient compensation for time and transportation costs	8.7	24.4	38.1	27.0	0	1.6
Childcare concerns	7.3	29.3	37.4	23.0	0	4.1
Length of study visits	14.8	25.0	41.9	15.3	0.8	2.4
Frequency of study visits	15.2	28.4	37.4	18.4	0.8	1.6

Industry interviews

Purpose

To identify industry perspectives on the slow progression of pediatric AB drug trials

Methods

In-depth interviews were conducted with 12 industry representatives who have experience with pediatric antibacterial drug development.

Main take home points

- Recruitment and enrollment are the main reasons for the slow progression of pediatric antibacterial clinical trials.
- Suggestions for simplifying antibacterial drug trials are to:
 - Use extrapolation
 - Reduce burden of trial participation for parents and children by limiting number of assessments, blood draws, and invasive procedures
 - Reduce burden among trial investigators by altering eligibility criteria to make trials easier to recruit, combining trials, and using pediatric trial sites

Table 5: Investigator Characteristics, n (%)

Variable	n=74
Specialty¹	
Pediatric infectious disease	35 (47.3)
Neonatologist	17 (23.0)
Pediatric intensivist	8 (10.8)
Pediatrician (general)	7 (9.5)
Pharmacologist	7 (9.5)
Pediatric hematologist/oncologist	0 (0)
Other ²	11 (14.9)
Years conducting pediatric antibacterial drug trials	
Less than 5 years	20 (27.0)
5-10 years	15 (20.3)
More than 10 years	39 (52.7)
Type of facility	
Academic children's hospital	64 (86.5)
Large community hospital (e.g. 100 beds)	7 (9.5)
Children's hospital (nonacademic)	4 (5.4)
Private clinic	3 (4.1)
Community clinic	0 (0)
Small community hospital	0 (0)
Other ³	7 (9.5)

¹Participant selected all that applied
²Pediatric hospital medicine, neonatal study coordinator, pediatric nephrologist, pediatric clinical pharmacology, pediatric pharmacist, pediatric cardiologist, pediatric emergency medicine, pediatric pulmonologist
³Pediatric clinical research unit/clinical research unit, academic general hospital/medical center, integrated health system

Table 6: Investigators' perceptions of potential barriers related to pediatric AB study protocols, ethics and regulatory processes, and colleagues' concerns about pediatric AB trials, %.

Category	Not a barrier	Somewhat	Moderate	Major	N/A	Not sure
Study Protocol, n=73						
Having overly narrow inclusion/exclusion criteria	9.4	16.4	38.1	42.5	0.8	1.4
Frequency of patient study visits	12.3	19.2	42.5	23.3	2.7	0.0
Amount of data to be collected at each study visit	19.2	45.2	24.0	8.2	0.8	0.0
Number of study procedures at each study visit	17.8	31.5	21.0	29.5	2.7	1.4
Length of patient study visits	28.5	32.9	30.1	17.2	4.1	0.0
Completing paper case report forms	42.5	31.5	19.2	1.4	1.6	4.1
Completing electronic case forms	45.2	31.5	15.1	4.1	1.4	2.7
Ethics and Regulatory, n=73						
Logistics of expeditiously obtaining consent from both parents	4.8	15.1	41.1	31.5	0.8	0.0
Obtaining parental consent when disagreement is evident	8.2	17.8	42.3	36.7	0.8	5.5
Obtaining parental consent	28.5	31.5	35.6	12.3	0.0	0.0
Preparing required regulatory documentation	31.5	35.6	28.8	4.1	0.0	0.0
Working through IRB questions and concerns	43.8	24.7	27.4	4.1	0.0	0.0
Obtaining child assent	35.6	31.5	12.3	4.1	16.4	0.0
Colleagues' Concerns, n=69						
Number of blood draws	15.9	37.7	32.8	21.7	0.0	0.0
Colleagues believe they know what is best for their patient	44.9	29.6	13.8	13.0	0.0	0.0
Perception that child will be at increased risk for physical harm	43.5	33.3	14.5	7.2	1.4	0.0
Colleagues would lose control of patient care	42.0	31.9	18.8	4.3	2.9	0.0
Concerns about the use of investigational agents	44.9	24.4	18.8	15.1	1.4	0.0

Funding and Disclosure: Funding for this work was made possible in part by the U.S. Food and Drug Administration through grant R01FD002922 and cooperative agreement U01FD002506. Views expressed in written materials or publications and by speakers and moderators do not necessarily reflect the official policies of the Department of Health and Human Services, nor does any mention of trade names, commercial practices, or organizations imply endorsement by the United States Government. Partial funding was also provided by pooled membership fees from the Clinical Trials Transformation Initiative's member organizations.

Acknowledgments: We gratefully acknowledge the participants who took part in these data collection activities and shared their experiences with us, as well as members of the full project team who provided their expertise in analyzing and interpreting the evidence.



Table 7: Investigators' perceptions of potential barriers related to parental concerns and parent or child logistics, %.

Category	Not a barrier	Somewhat	Moderate	Major	N/A	Not sure
Parental Concerns, n=72						
Concerns about number of blood draws	0.0	16.7	34.7	47.2	1.4	0.0
Concerns about the side effects of the drug	4.2	23.9	33.5	14.9	1.4	0.0
Concerns about the number of invasive procedures	0.0	16.7	31.9	43.1	8.3	0.0
Concerns about child taking a drug not previously tested in children	8.3	24.4	27.5	25.0	1.4	1.4
Concerns about consent length and complexity	11.1	30.4	29.2	24.4	2.8	0.0
Perception that the child will be at increased risk for physical harm	11.1	32.3	30.3	20.8	1.4	0.0
Concerns about being randomized to placebo	11.1	40.3	30.6	12.0	4.2	1.4
Concerns about blinding/not knowing which drug their child would be taking	14.9	28.8	23.8	21.1	1.4	0.0
Concerns about blinding/not knowing which drug their child would be taking	27.8	30.4	27.8	11.1	2.8	0.0
Parent and Child Logistics, n=71						
Parents' work schedules	4.2	31.0	31.0	26.4	7.0	0.0
Transportation difficulties for parents/children	5.7	30.0	30.0	24.3	10.0	0.0
Frequency of study visits	14.1	21.1	31.0	19.7	5.6	0.0
Children's school schedules	8.5	31.0	31.0	15.5	14.1	0.0
Childcare concerns	14.1	31.0	30.0	18.0	8.5	0.0
Length of study visits	19.7	28.8	38.0	9.7	5.6	0.0
Insufficient compensation for time and transportation	16.9	25.4	29.6	18.3	9.9	0.0
Miscellaneous, n=71						
Insufficient budget to cover trial costs	8.5	22.9	26.8	38.0	2.8	2.8
Child does not want to participate in study	32.4	28.8	9.7	11.3	18.3	1.4

Parent interviews

Purpose

- To gain a better understanding of the factors involved in parents' decision-making about whether to enroll their child in a clinical trial, with particular attention to the barriers to enrollment and ways to overcome them when possible.
- To better understand parents' perceptions about the kinds of approaches that are most effective, and the kinds of information and level of detail parents want about the potential risks and benefits of trial participation.

Methods

- In August 2015, 24 in-depth telephone interviews were conducted with parents whose children were offered an opportunity to participate in a clinical trial.
- The children ranged in age from neonates to teenagers, represented a national geographic mix and had a wide variety of conditions and illnesses, including lung infections, asthma, allergies, autoimmune diseases, cystic fibrosis and ADHD.

Based on these interviews, we offer the following 10 strategies that will help increase the success rate of clinical trial recruitment.

The Initial Contact

- The initial contact with parents is best made by the child's own pediatrician or a health care provider who has already been participating in their child's medical care, rather than a stranger on the study team. The trust factor in such providers is key.
- If the initial contact must be made by a "stranger" on the study team, provide them with sensitivity training on best ways to approach parents, e.g., knowing the child's name and understanding their medical situation. Spending the extra time to show empathy and concern for the family's predicament is extremely important.
- When recruiting premature newborns into clinical trials, do not approach parents in the first few days after the birth of the baby so as not to add additional their stress and anxiety at such a difficult time.
- Remember that parents would strongly welcome the opportunity to communicate with other parents who have enrolled their child in the trial in question, and facilitate those connections.
- Flexible scheduling of appointments is necessary. Working parents and older children need to be able to schedule study appointments that allow them to carry out their other responsibilities. Provide weekend and evening appointment hours. Consider letting families who live far from the study site have some of the study monitoring visits completed by their child's own pediatrician. Consider sending a nurse to the child's home for some of the visits.
- Tell parents how the clinical trial could directly benefit their particular child, and let them know that their child's safety and wellbeing are of primary importance to those conducting the study.
- Tell parents about the potential benefits of the study with realistic expectations. Make them aware of all possible risks and side effects their child could experience and whether each is probable, possible or extremely rare. Let them know that, should their child experience a side effect, they will have access to a study team member to help them 24/7.
- Make the clinical trial kid-friendly:
 - For young children, friendly people; fun activities; and kid-friendly environment are important. Access to toys, games, and videos at the study site will encourage them to want to go back for future appointments.
 - For older children, incentivize them with money or money substitute (gift cards; on line credits) that provide them the opportunity to get things they would not otherwise have.

After the Study

- Tell the parents about the study findings when they become available, either in a letter, or by providing them with a published article.
- Parents whose children have had positive experiences in clinical trials are more likely to enroll them in subsequent studies, especially with the same study team. Remembering to show special appreciation to the family for their participation in the clinical trial can bring future benefits.